When was Septerna founded?

Septerna was founded in 2020 and raised its 1st funding round 2 years after it was founded.

Where is Septerna located?

Septerna is headquartered in San Bruno, United States.

How many employees does Septerna have?

As of Sep 30, 2026, the latest employee count at Septerna is 139.

Is Septerna a funded company?

Septerna is a funded company, having raised a total of $250M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jan 27, 2022.

When was the latest funding round of Septerna?

Septerna's latest funding was a $***** Series B round on Jul 11, 2023, with participation from 15 investors. Its primary sector is Immunology. In United States, the Immunology sector has seen $4.27B in funding in 2026 to date.

What is the annual revenue of Septerna?

Annual revenue of Septerna is between $10M and $50M as on Dec 31, 2025

Where does Septerna rank among its competitors?

Septerna ranks 42nd amongst 3199 active competitors, of which 1075 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Septerna?

Septerna's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Immuneel secured the most recent funding round in June, 2026.

Septerna - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of GPCR drug discovery platform for multiple diseases. The company combines biochemical, structural, and computational drug discovery approaches and uses a Native Complex platform for GPCR targeted small molecules against endocrinology, central nervous system, metabolic disease, and inflammation disorders.

Website: septerna.com
Social
Email ID: *****@septerna.com
Phone Number: +1 **********

Key Metrics

Founded Year

2020

Location

San Bruno, United States

Stage

Public

Total Funding

$250M in 2 rounds

Latest Funding Round

Series B, Jul 11, 2023, $*****

Investors

Third Rock Ventures & 15 more

Ranked

42^nd among 3199 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2025

Employee Count

139 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 976 more

Exit Details

Public

View Septerna's full profile

Septerna is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Septerna, Inc. CIN: 1984086 , United States, Active		$10M - $50M (As on Dec 31, 2025)	-	-

Septerna got listed on Oct 25, 2024.

Click here to take a look at Septerna's IPO in detail

Septerna has raised a total funding of $250M over 2 rounds. Its first funding round was on Jan 27, 2022. Its latest funding round was a Series B round on Jul 11, 2023 for $*****. 15 investors participated in its latest round. Septerna has 16 institutional investors.

Here is the list of recent funding rounds of Septerna:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 11, 2023	1894142	Series B	7600686	1120049	1891010	2964061
Jan 27, 2022	7210016	Series A	1310592	1038614	Third Rock Ventures	Samsara BioCapital & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Septerna's funding rounds and investors

The founders of Septerna is Ali Masoudi.

Here are the details of Septerna's key team members:

Ali Masoudi: CEO and Co-Founder of Septerna.
Contact Info: 1 email address

View details of Septerna's Founder profiles and Board Members

Septerna's employee count trend

Septerna has 139 employees as of Sep 26. Here is Septerna's employee count trend over the years:

Uncover Septerna's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Septerna include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Septerna, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
5th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
8th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
9th	Deciphera 2003, Waltham (United States), Acquired	Developer of type 2 kinase inhibitors for treating cancer	$173M	Redmile Group, New Leaf Venture Partners & 4 others	70/100
10th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	70/100
42nd	Septerna 2020, San Bruno (United States), Public	Developer of GPCR drug discovery platform for multiple diseases	$250M	BVF Partners, RA Capital Management & 14 others	66/100